Format

Send to

Choose Destination
JAMA Netw Open. 2019 May 3;2(5):e194573. doi: 10.1001/jamanetworkopen.2019.4573.

Development and Validation of an Esophageal Squamous Cell Carcinoma Detection Model by Large-Scale MicroRNA Profiling.

Author information

1
Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
2
Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.
3
Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
4
Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan.
5
Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
6
Department of Esophageal Surgery, National Cancer Center Hospital, Tokyo, Japan.
7
Toray Industries, Inc, Kamakura, Japan.
8
Dynacom Co, Mihama, Japan.
9
Department of Biobank and Tissue Resources, National Cancer Center Research Institute, Tokyo, Japan.
10
Medical Genome Center, National Center for Geriatrics and Gerontology, Obu, Japan.
11
Fundamental Innovative Oncology Core Center, National Cancer Center Research Institute, Tokyo, Japan.
12
Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

Abstract

Importance:

Patients with late-stage esophageal squamous cell carcinoma (ESCC) have a poor prognosis. Noninvasive screening tests using serum microRNAs (miRNAs) to accurately detect early-stage ESCC are needed to improve mortality.

Objective:

To establish a model using serum miRNAs to distinguish patients with ESCC from noncancer controls.

Design, Setting, and Participants:

In this case-control study, serum miRNA expression profiles of patients with ESCC (nā€‰=ā€‰566) and control patients without cancer (nā€‰=ā€‰4965) were retrospectively analyzed to establish a diagnostic model, which was tested in a training set and confirmed in a validation set. Patients histologically diagnosed as having ESCC who did not receive prior therapy or have a past or concurrent cancer other than ESCC were enrolled from the National Cancer Center Hospital in Tokyo, Japan. Between October 2010 and November 2015, control samples were collected from the National Cancer Center Biobank, the Biobank of the National Center for Geriatrics and Gerontology, and the general population undergoing routine health examination. Data analysis was performed between August 2015 and October 2018. Serum samples were randomly divided into discovery and validation sets.

Main Outcomes and Measures:

The expression of 2565 miRNAs was assessed in each sample. The discriminant model (named the EC index) was evaluated in the training set using Fisher linear discriminant analysis with a greedy algorithm. Receiver operating characteristic curve analysis evaluated the diagnostic ability of the model in the validation set.

Results:

In the training set, 283 patients with esophageal cancer (median age, 67 years [range, 37-90 years]; 83.4% male) were compared with 283 control patients (median age, 54 years [range, 22-100 years]; 43.1% male), and the EC index was constructed using 6 miRNAs (miR-8073, miR-6820-5p, miR-6794-5p, miR-3196, miR-744-5p, and miR-6799-5p). The area under the receiver operating characteristic curve was 1.00, with sensitivity of 1.00 and specificity of 0.98. The validation set included 283 patients (median age, 66 years [range, 42-87 years]; 83.0% male) and 4682 control patients (median age, 68 years [range, 20-98 years]; 44.7% male), and the area under the receiver operating characteristic curve for the EC index was 1.00, with sensitivity of 0.96 and specificity of 0.98.

Conclusions and Relevance:

What appears to be novel serum miRNA discriminant model was developed for the diagnosis of ESCC. A multicenter prospective study is ongoing to confirm the present observations.

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center